Mi-Young Park

Mi-Young Park

Auto-generated profile, based on publicly available information

Mi-Young Park

AMOREPACIFIC R&D Center, 1920, Youngu‐daero, Giheung‐gu, Yongin‐si Gyeonggi‐do Republic of Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
YLY.W. Lee
Y.W. Lee
CWC.‐H. Won
C.‐H. Won
KJK. Jung
K. Jung
HNH.‐J. Nam
H.‐J. Nam
GCG. Choi
G. Choi
Beomjoon KimBeomjoon Kim
Beomjoon Kim
Background Transient receptor potential vanilloid subfamily, member 1 (TRPV1) may play an important role in pruritus and inflammation induction in atopic dermatitis (AD). The treatment effect of TRPV1 antagonist via topical application in patients with AD remains unknown. Objectives To assess the clinical efficacy and safety of PAC‐14028, a TRPV1 antagonist, via topical application in patients with AD. Methods In this 8‐week, phase IIb, randomized, double‐blind, multicentre, vehicle‐controlled study, patients with mild‐to‐moderate AD were randomized to receive PAC‐14028 cream 0·1%, 0·3%, 1·0% or vehicle cream twice daily. The primary efficacy end point was the Investigator's Global Assessment (IGA) success rate defined as the percentage of patients with an IGA score of 0 or 1 at week 8. The secondary efficacy end points included the severity Scoring of Atopic Dermatitis (SCORAD) index and Eczema Area and Severity Index (EASI) 75/90. Results A total of 194 patients were enrolled. IGA success rates at week 8 were 14·58% for vehicle cream, 42·55% for PAC‐14028 cream 0·1% (P = 0·0025 vs. vehicle), 38·30% for PAC‐14028 cream 0·3% (P = 0·0087 vs. vehicle) and 57·45% for PAC‐14028 cream 1·0% (P < 0·001 vs. vehicle). In particular, statistically significant differences were found between the vehicle and treatment groups in the IGA success rates with two‐grade improvement. The SCORAD index, EASI 75/90, sleep disturbance score and pruritus visual analogue scale showed a trend towards improvement. No significant safety issues were reported. Conclusions PAC‐14028 cream may be an effective and safe treatment modality for the treatment of patients with mild‐to‐moderate AD.

28 April 2020 in Journal of the Science of Food and Agriculture
Verified
Journal Article
Closed access
PDF file
YLYEONGEUN LEE
YEONGEUN LEE
SYSo‐Hee Yoo
So‐Hee Yoo
JCJINOH CHUNG
JINOH CHUNG
MPMi‐Young Park
Mi‐Young Park
YHYong‐Deog Hong
Yong‐Deog Hong
SSSoon-Mi Shim
Soon-Mi Shim

20 March 2020 in Food & Function
Verified
Journal Article
Closed access
PDF file
SYSo-Hee Yoo
So-Hee Yoo
YLYEONGEUN LEE
YEONGEUN LEE
JCJINOH CHUNG
JINOH CHUNG
CRChan-Su Rha
Chan-Su Rha
YHYong-Deog Hong
Yong-Deog Hong
SSSoon-Mi Shim
Soon-Mi Shim
Results from the current study suggested that whole green tea components rich in flavonols and polysaccharides could be potential hypoglycemic excipient ingredients into green tea catechins by enhancing catechin absorption.